A Pilot Study to Evaluate the Efficacy of Fosaprepitant and Granisetron Transdermal System for the Prevention of Acute and Delayed Nausea and Vomiting in Breast Cancer Patients and to Identify Predictors of Response

Trial Profile

A Pilot Study to Evaluate the Efficacy of Fosaprepitant and Granisetron Transdermal System for the Prevention of Acute and Delayed Nausea and Vomiting in Breast Cancer Patients and to Identify Predictors of Response

Discontinued
Phase of Trial: Phase III

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Fosaprepitant (Primary) ; Granisetron (Primary)
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 18 Apr 2017 Planned End Date changed from 1 Sep 2017 to 4 Sep 2018.
    • 18 Apr 2017 Planned primary completion date changed from 1 Sep 2016 to 4 Sep 2017.
    • 18 Apr 2017 Status changed from recruiting to discontinued due to Lack of Efficacy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top